LONGBIO-B
0177918AListed醫療健康 · 一家专注于过敏及自身免疫性疾病领域的生物制药公司，致力于创新药物的研发与商业化。
High attention
81.9
/100
- Offer price
- HK$96.06
- Final offer price
- HK$96.06
- Lot / entry fee
- 50 shares · HK$5K
- Proceeds
- HK$1.36B
- Sponsor
- Sinolink Securities
- Est. margin oversub.
- 3831.8x
- Public oversub.
- 4762.6x
- One-lot win rate
- 2.0%
- First-day return
- +37.2%
Offer starts
May 28
Offer closes
Jun 2
Grey market
Jun 4
Listing
Jun 5
AI reference scoring and scenarios
After grey market
After grey market L1 heat score
81.9/ 100
Data coverage High
Target
Historical calibration
Listing-day trend
Strong positivePartial basis
Up probability
97.8%
First-day reference range
+45.9% – +127.2%
Published outcome check
First-day resultBig up+37.2%
Our call: Trend call valid
Covered 19/25 core factors
UsedMissingNot yet scorableN/A
Margin oversubscription
High heatOffer size
Weaker qualityCornerstone lockup
Strong supportPost-lockup offer value
Medium scarcityRecent same-rule trend
Strong trendRecent same-type trend
Strong trendRecent sector trend
Strong trendValuation
Average appealFundamental quality
Average qualityGrowth quality
—Profitability
Weak qualityCash runway
High qualityCustomer concentration
—Cornerstone quality
Strong supportSponsor record
Strong recordGreenshoe arrangementGreenshoe: yes · 15%
Average supportStabilizer track record
—A-share pre-grey trend
—A-share listing-day trend
—Public oversubscription
High heatOne-lot win rate
High heatInternational placing
High heatFinal pricing position
—Actual greenshoe useCumulative use 0.0%
Good supportGrey market return
Strong trendThe assessment and probability ranges are informational only and are not investment advice.
AI Research Report
After grey marketThe analysis report for this IPO is being generated.